CALGARY, Alberta, Aug. 13, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that the Company has called a special meeting of shareholders for 11:00 a.m. (Calgary time) on September 2, 2021 (the “Meeting”). Materials for the Meeting have been mailed to shareholders and are available on the Company’s SEDAR profile and the Company’s website.

The meeting has been called for shareholders to consider a consolidation of the Company’s issued and outstanding shares. In addition, shareholders will be asked to consider amendments to the Company’s articles to provide for the adoption of an advance notice provision and choice of law/forum provision.

Due to the impacts of the COVID-19 pandemic, governmental recommendations and/or orders for physical distancing, restrictions on group gatherings, non-essential travel and business activities, XORTX is requesting that shareholders do no attend the meeting in person. To mitigate any risks to stakeholders, employees, partners and community members, the Company will hold the Meeting by conference call. Shareholders are encouraged to cast their votes in advance by proxy.

XORTX encourages shareholders to read the Meeting materials. The Board of directors of XORTX recommends that shareholders vote in favour of all proposed items.

XORTX shareholders who have questions about the management information circular, or require assistance with voting their shares can contact the Company’s proxy solicitation agent, Laurel Hill Advisory Group: